Publications

BibTex format

@article{Morgan:2021:10.1016/S1470-2045(20)30591-X,
author = {Morgan, RD and McNeish, IA and Cook, AD and James, EC and Lord, R and Dark, G and Glasspool, RM and Krell, J and Parkinson, C and Poole, CJ and Hall, M and Gallardo-Rincón, D and Lockley, M and Essapen, S and Summers, J and Anand, A and Zachariah, A and Williams, S and Jones, R and Scatchard, K and Walther, A and Kim, J-W and Sundar, S and Jayson, GC and Ledermann, JA and Clamp, AR},
doi = {10.1016/S1470-2045(20)30591-X},
journal = {The Lancet Oncology},
pages = {277--288},
title = {Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial},
url = {http://dx.doi.org/10.1016/S1470-2045(20)30591-X},
volume = {22},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and cancer antigen 125 (CA125) has not been reported. We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 trial. METHODS: ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. The trial included women aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of more than 12 weeks, and newly diagnosed International Federation of Gynecology and Obstetrics (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grade 3 histological subtype, or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube, or primary peritoneum. Patients were randomly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m2 by body surface area) on day 1 of every 21-day cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 2); or intravenous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 3). The maximum number of cycles of chemotherapy permitted was six. Randomisation was done with a minimisation method, and patients were stratified accordi
AU  - Morgan,RD
AU  - McNeish,IA
AU  - Cook,AD
AU  - James,EC
AU  - Lord,R
AU  - Dark,G
AU  - Glasspool,RM
AU  - Krell,J
AU  - Parkinson,C
AU  - Poole,CJ
AU  - Hall,M
AU  - Gallardo-Rincón,D
AU  - Lockley,M
AU  - Essapen,S
AU  - Summers,J
AU  - Anand,A
AU  - Zachariah,A
AU  - Williams,S
AU  - Jones,R
AU  - Scatchard,K
AU  - Walther,A
AU  - Kim,J-W
AU  - Sundar,S
AU  - Jayson,GC
AU  - Ledermann,JA
AU  - Clamp,AR
DO  - 10.1016/S1470-2045(20)30591-X
EP  - 288
PY  - 2021///
SN  - 1213-9432
SP  - 277
TI  - Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
T2  - The Lancet Oncology
UR  - http://dx.doi.org/10.1016/S1470-2045(20)30591-X
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33357510
UR  - https://www.sciencedirect.com/science/article/pii/S147020452030591X?via%3Dihub
UR  - http://hdl.handle.net/10044/1/85291
VL  - 22
ER  -

Download

DrJonathanKrell

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)